Literature DB >> 32321805

Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology.

Jie Yang1, Chen Ma2, Yu Zhao1, Anjing Fan2, Xiufen Zou2, Zishu Pan3.   

Abstract

Respiratory syncytial virus (RSV) is the most important cause of lower respiratory tract infection in infants and young children. The vaccine-enhanced disease (VED) has greatly hindered the development of an RSV vaccine. Currently, there are no licensed vaccines for RSV. In this study, immunization of mice with hepatitis B virus core particles containing a conserved region of the G protein (HBc-tG) combined with interleukin-35 (IL-35) elicited a Th1-biased response and a high frequency of regulatory T (Treg) cells and increased the levels of IL-10, transforming growth factor β, and IL-35 production. Importantly, immunization with HBc-tG together with IL-35 protected mice against RSV infection without vaccine-enhanced immunopathology. To explore the mechanism of how IL-35 reduces lung inflammation at the gene expression level, transcription profiles were obtained from lung tissues of immunized mice after RSV infection by the Illumina sequencing technique and further analyzed by a systems biology method. In total, 2,644 differentially expressed genes (DEGs) were identified. Twelve high-influence modules (HIMs) were selected from these DEGs on the basis of the protein-protein interaction network. A detailed analysis of HIM10, involved in the immune response network, revealed that Il10 plays a key role in regulating the host response. The selected DEGs were consistently confirmed by quantitative real-time PCR (qRT-PCR). Our results demonstrate that IL-35 inhibits vaccine-enhanced immunopathology after RSV infection and has potential for development in novel therapeutic and prophylactic strategies.IMPORTANCE In the past few decades, respiratory syncytial virus (RSV) has still been a major health concern worldwide. The vaccine-enhance disease (VED) has hindered RSV vaccine development. A truncated hepatitis B virus core protein vaccine containing the conserved region (amino acids 144 to 204) of the RSV G protein (HBc-tG) had previously been shown to induce effective immune responses and confer protection against RSV infection in mice but to also lead to VED. In this study, we investigated the effect of IL-35 on the host response and immunopathology following RSV infection in vaccinated mice. Our results indicate that HBc-tG together with IL-35 elicited a balanced immune response and protected mice against RSV infection without vaccine-enhanced immunopathology. Applying a systems biology method, we identified Il10 to be the key regulator in reducing the excessive lung inflammation. Our study provides new insight into the function of IL-35 and its regulatory mechanism of VED at the network level.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Il10zzm321990; interleukin-35; regulatory T cells; respiratory syncytial virus; transcriptome analysis; vaccine-enhanced disease

Year:  2020        PMID: 32321805      PMCID: PMC7307162          DOI: 10.1128/JVI.00007-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

Review 2.  Interleukin-10 in the regulation of T cell-induced colitis.

Authors:  Oliver Annacker; Chrystelle Asseman; Simon Read; Fiona Powrie
Journal:  J Autoimmun       Date:  2003-06       Impact factor: 7.094

3.  Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Authors:  Fu-Shi Quan; Yonghwan Kim; Sujin Lee; Hong Yi; Sang-Moo Kang; Jadranka Bozja; Martin L Moore; Richard W Compans
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

Review 4.  Advances in RSV vaccine research and development - A global agenda.

Authors:  Deborah Higgins; Carrie Trujillo; Cheryl Keech
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

5.  Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response.

Authors:  M Román; W J Calhoun; K L Hinton; L F Avendaño; V Simon; A M Escobar; A Gaggero; P V Díaz
Journal:  Am J Respir Crit Care Med       Date:  1997-07       Impact factor: 21.405

6.  IL-35 Decelerates the Inflammatory Process by Regulating Inflammatory Cytokine Secretion and M1/M2 Macrophage Ratio in Psoriasis.

Authors:  Junfeng Zhang; Yi Lin; Chunlei Li; Xiaomei Zhang; Lin Cheng; Lei Dai; Youcui Wang; Fangfang Wang; Gang Shi; Yiming Li; Qianmei Yang; Xueliang Cui; Yi Liu; Huiling Wang; Shuang Zhang; Yang Yang; Rong Xiang; Jiong Li; Dechao Yu; Yuquan Wei; Hongxin Deng
Journal:  J Immunol       Date:  2016-08-15       Impact factor: 5.422

Review 7.  Molecular epidemiology of respiratory syncytial virus.

Authors:  Krisna N A Pangesti; Moataz Abd El Ghany; Michael G Walsh; Alison M Kesson; Grant A Hill-Cawthorne
Journal:  Rev Med Virol       Date:  2018-01-29       Impact factor: 6.989

8.  A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease.

Authors:  Chaofan Li; Xian Zhou; Yiwei Zhong; Changgui Li; Aihua Dong; Zhonghuai He; Shuren Zhang; Bin Wang
Journal:  J Immunol       Date:  2016-01-20       Impact factor: 5.422

Review 9.  The CD4 T cell response to respiratory syncytial virus infection.

Authors:  Allison F Christiaansen; Cory J Knudson; Kayla A Weiss; Steven M Varga
Journal:  Immunol Res       Date:  2014-08       Impact factor: 4.505

10.  Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice.

Authors:  Lydia R Durant; Spyridon Makris; Cornelia Maaike Voorburg; Jens Loebbermann; Cecilia Johansson; Peter J M Openshaw
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

View more
  4 in total

Review 1.  The Role of IL-35 in the Pathophysiological Processes of Liver Disease.

Authors:  Shuang Hu; Pan-Pan Lian; Ying Hu; Xing-Yu Zhu; Shao-Wei Jiang; Qiang Ma; Liang-Yun Li; Jun-Fa Yang; Li Yang; Hai-Yue Guo; Hong Zhou; Chen-Chen Yang; Xiao-Ming Meng; Jun Li; Hai-Wen Li; Tao Xu; Huan Zhou
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

2.  Dynamic Host Immune and Transcriptomic Responses to Respiratory Syncytial Virus Infection in a Vaccination-Challenge Mouse Model.

Authors:  Yu Zhao; Chen Ma; Jie Yang; Xiufen Zou; Zishu Pan
Journal:  Virol Sin       Date:  2021-06-17       Impact factor: 6.947

3.  Interleukin-35 Is Involved in Angiogenesis/Bone Remodeling Coupling Through T Helper 17/Interleukin-17 Axis.

Authors:  Hui Zhang; Yuxuan Li; Lin Yuan; Lutian Yao; Jie Yang; Liping Xia; Hui Shen; Jing Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-16       Impact factor: 5.555

Review 4.  Functional Features of the Respiratory Syncytial Virus G Protein.

Authors:  Larry J Anderson; Samadhan J Jadhao; Clinton R Paden; Suxiang Tong
Journal:  Viruses       Date:  2021-07-01       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.